Carregant...
Lutetium Lu-177 Dotatate Flare Reaction
PURPOSE: Lutetium Lu-177 dotatate is the first peptide receptor radionuclide therapy approved by the US Food and Drug Administration. Well-designed studies in Europe have shown dramatic effectiveness in improving progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors...
Guardat en:
| Publicat a: | Adv Radiat Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7811111/ https://ncbi.nlm.nih.gov/pubmed/33490736 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.adro.2020.11.008 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|